Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

William J. Jusko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4027-0550; OpenAlex author ID A5021901997; NIH RePORTER profile ID 1897079. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 11)
Trials
0
Grants
1
Labs led
2
Collaborators
13
Papers, trials and grants by year

2013: 3 papers · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 grant · 2024: 2 papers

Papers 14

  1. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tu… Last author DOI 10.1016/j.xphs.2023.10.030↗
  2. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathw… Last author DOI 10.1016/j.xphs.2023.10.036↗
  3. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1016/j.mcpro.2022.100409↗
  4. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Co-author DOI 10.1124/jpet.120.000412↗
  5. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. Last author DOI 10.1002/psp4.12320↗
  6. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. Last author DOI 10.1007/s10928-018-9603-z↗
  7. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. First author DOI 10.1208/s12248-018-0235-4↗
  8. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Last author DOI 10.3389/fphar.2018.00084↗
  9. Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Last author DOI 10.1007/s00280-015-2907-4↗
  10. Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. Last author DOI 10.3389/fphar.2016.00421↗
  11. Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Last author DOI 10.1007/s10928-015-9429-x↗
  12. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Last author DOI 10.1007/s00280-013-2117-x↗
  13. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Last author DOI 10.1007/s00280-013-2226-6↗
  14. Interactions of everolimus and sorafenib in pancreatic cancer cells. Last author DOI 10.1208/s12248-012-9417-7↗

Grants 1

  1. Mechanistic Pharmacokinetics and Pharmacodynamics R35GM131800↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert M. Straubinger · 13 shared papers, 2013–2024 · strength 1.47
  2. Jun Qu · 5 shared papers, 2018–2024 · strength 0.80
  3. Xin Miao · 4 shared papers, 2016–2024 · strength 0.60
  4. Qingxiang Lin · 2 shared papers, 2021–2022 · strength 0.32
  5. Xu Zhu · 3 shared papers, 2015–2018 · strength 0.31
  6. Wen Wee Ma · 3 shared papers, 2013–2021 · strength 0.25
  7. Xue Wang · 1 shared paper, 2024 · strength 0.22
  8. Emilie A.G. Molins · 1 shared paper, 2018 · strength 0.17
  9. Donald E. Mager · 1 shared paper, 2021 · strength 0.16
  10. Sailee Suryakant Rasam · 1 shared paper, 2022 · strength 0.16
  11. Xu Zhu · 1 shared paper, 2018 · strength 0.11
  12. Dipti K. Pawaskar · 2 shared papers, 2013 · strength 0.09
  13. Salaheldin S. Hamed · 1 shared paper, 2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.